These drugs such as HER2, ALK, EGFR, and ROS1 are keywords that appear more frequently in recent articles related to anticancer drugs Effective treatments for patients vary depending on what genetic mutations the patient has. Starting with treatment HER2, ALK, EGFR, etc., which show excellence in patients in certain conditions, drugs targeting gene mutations such as ROS, NTRK, and RET are now emerging.

Advances in precision medicine now herald a shift in prescription standards for drugs from disease to genetic. The era of customized medical care has arrived. Can the Korean system handle these drugs that are effective if genetic mutations are identified regardless of cancer species?

It is